The evolution of the acute response to L-dopa in Parkinson's disease

被引：0
|
作者：
Hughes, AJ
Lees, AJ
机构：
来源：
MOVEMENT DISORDERS | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P282
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [41] Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients
    O. Bartošová
    C. Bonnet
    O. Ulmanová
    M. Šíma
    F. Perlík
    E. Růžička
    O. Slanař
    Journal of Neural Transmission, 2018, 125 : 699 - 703
  • [42] L-dopa therapy for Parkinson's disease: Past, present, and future
    Nagatsu, Toshiharu
    Sawada, Makoto
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S3 - S8
  • [43] L-dopa related hyperhomocysteinemia and development of dementia in Parkinson's disease
    dell'Aquila, C.
    Zoccolella, S.
    Mascolo, L.
    Abruzzese, G.
    Antonini, A.
    Bonuccelli, U.
    Dlazio, G.
    Pacchetti, C.
    Lamberti, P.
    MOVEMENT DISORDERS, 2008, 23 (01) : S249 - S249
  • [44] Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa
    A. W. Michell
    Z. Xu
    D. Fritz
    S. J. G. Lewis
    T. Foltynie
    C. H. Williams-Gray
    T. W. Robbins
    R. H. S. Carpenter
    R. A. Barker
    Experimental Brain Research, 2006, 174 : 7 - 18
  • [45] Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients
    Bartosova, O.
    Bonnet, C.
    Ulmanova, O.
    Sima, M.
    Perlik, F.
    Ruzicka, E.
    Slanar, O.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (04) : 699 - 703
  • [46] Disease progression and increased L-dopa efficacy with time in Parkinson's disease
    Holford, NHG
    Chan, PLS
    Lee, YY
    Nutt, JG
    MOVEMENT DISORDERS, 2002, 17 : S112 - S112
  • [47] Molecular mechanism of L-Dopa induced dyskinesia in Parkinson's disease
    Subhani, F. U. -H.
    Subhani, A.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S118 - S119
  • [48] Arguments favoring early treatment of Parkinson's disease with L-Dopa
    Broussolle, E
    REVUE NEUROLOGIQUE, 1999, 155 (01) : 27 - 33
  • [49] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    MOVEMENT DISORDERS, 2011, 26 : S259 - S259
  • [50] L-dopa impairs learning, but spares generalization, in Parkinson's disease
    Shohamy, D
    Myers, CE
    Geghman, KD
    Sage, J
    Gluck, MA
    NEUROPSYCHOLOGIA, 2006, 44 (05) : 774 - 784
12345